Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 ) FDA label
Also known as Latanoprost 0.005% Ophthalmic Solution (XALATAN), Latanoprost ophthalmic solution
Xalatan · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Xalatan | DRUG | - |
Inclusion Criteria: * Open-angle glaucoma * ocular hypertension Exclusion Criteria: \- VA worse than 0.60
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
Xalatan is an investigational small molecule being developed for open-angle glaucoma. It is a topical ophthalmic solution studied in patients with open-angle glaucoma or ocular hypertension. The drug is in Phase 2 clinical development and is not yet approved by the FDA.
Xalatan is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker ALC. Alcon is conducting clinical research on this ophthalmic solution for the treatment of open-angle glaucoma.
Xalatan is in Phase 2 clinical development. It has completed one Phase 2 trial and is currently not in any active trials. The drug remains investigational and has not received FDA approval.
Xalatan has been studied in one completed Phase 2 clinical trial, NCT00465621, titled "Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension." The trial enrolled 150 participants in the United States and was randomized and double-blind.
Yes, Xalatan is also known as AL-37807. The clinical trial NCT00465621 refers to the drug as AL-37807 ophthalmic solution, which is the same investigational product being developed by Alcon for open-angle glaucoma.